Baroreflex sensitivity but not microvolt T-wave alternans can predict major adverse cardiac events in ischemic heart

Damian K Kaufmann1, Grzegorz Raczak2, Małgorzata Szwoch2

  • 1Department of Cardiology and Electrotherapy, Medical University of Gdansk, Poland. pestkowy@gmail.com.

Cardiology Journal
|October 1, 2020
PubMed

Insights

Baroreflex sensitivity (BRS) and left ventricular ejection fraction (LVEF) independently predict major adverse cardiovascular events (MACE) in ischemic heart failure patients. Low BRS (≤ 3 ms/mmHg) and LVEF (≤ 33%) indicate the highest MACE risk.

Area of Science:

  • Cardiology
  • Autonomic Nervous System Research
  • Heart Failure Management

Background:

  • Major adverse cardiovascular events (MACE) are a primary cause of mortality in ischemic heart failure (HF).
  • The prognostic value of autonomic nervous system parameters and microvolt T-wave alternans (MTWA) in HF patients remains unclear.
  • This study aimed to evaluate these parameters for MACE prediction in ischemic HF with left ventricular systolic dysfunction.

Purpose of the Study:

  • To assess the predictive value of baroreflex sensitivity (BRS) and microvolt T-wave alternans (MTWA) for MACE in ischemic heart failure patients.
  • To identify independent predictors of MACE in this population.
  • To establish cut-off values for key parameters associated with MACE risk.

Main Methods:

  • Analysis of BRS, heart rate variability (HRV), MTWA, and clinical data in 188 ischemic HF outpatients (LVEF ≤ 50%).
  • Follow-up duration of 34 months (range 14-71) with endpoint recording.
  • Univariate and multivariate Cox regression analyses to identify MACE predictors.

Main Results:

  • Univariate analysis identified BRS, MTWA, age, NYHA class III, LVEF, ICD presence, diuretic/antiarrhythmic use, diabetes, and kidney insufficiency as MACE predictors.
  • Multivariate analysis confirmed BRS (HR 2.97) and LVEF (HR 1.98) as independent predictors.
  • Significant cut-off values were BRS ≤ 3 ms/mmHg and LVEF ≤ 33%.

Conclusions:

  • BRS and LVEF are independent predictors of MACE in ischemic HF patients with LVEF ≤ 50%.
  • Specific thresholds (BRS ≤ 3 ms/mmHg, LVEF ≤ 33%) identify patients at highest risk for MACE.
  • These findings aid in risk stratification and management of ischemic heart failure.
Abstract

Related Concept Videos

Measurement of Blood Pressure01:17

Measurement of Blood Pressure

Assessing blood pressure is a standard procedure executed in virtually all medical environments. The method utilized today was established over a hundred years ago by an innovative Russian doctor, Dr. Nikolai Korotkoff. The soft ticking noise, known as Korotkoff sounds, heard while taking blood pressure readings results from turbulent blood flow within the vessels. The apparatus required for this procedure includes a sphygmomanometer, a blood pressure cuff attached to a gauge, and a...
2.3K
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
118
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
726